Frequently Asked Questions
The market is segmented based on , By Disease Type (Gastroenteritis, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome and Others), Molecular targets (Sodium Transporter NHE3 Inhibitor, Sphinogosine-1-Phosphate Receptor Functional Antagonist, Tumor Necrosis Factor (TNF) Blocker and Others), Marketed Drugs (Infliximab, Adalimumab, Mesalazine and Others), Clinical Trials (Etrolizumab, SHP647, ABX464, ASP3291 and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
.
The Global Gastrointestinal Diseases Drug Development Market size was valued at USD 37114.12 USD Million in 2022.
The Global Gastrointestinal Diseases Drug Development Market is projected to grow at a CAGR of 3.3% during the forecast period of 2023 to 2030.
The major players operating in the market include GSK, F. Hoffmann, La Roche, Novartis, AstraZeneca, Pfizer, Bristol Myers Squibb, Sanofi, Amgen, Daiichi Sankyo, AB Sciences, Eisai, Genentech, Merck & Co..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
